{"filing":{"accession_number":"0001171843-26-006753","cik":"0001447028","ticker":"ABUS","company_name":"Arbutus Biopharma Corp","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-20","primary_document":"f8k_102126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326006753/f8k_102126.htm"},"events":[{"id":37042,"run_id":34142,"accession_number":"0001171843-26-006753","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The FDA's lifting of the clinical hold on AB-101's IND application is a material regulatory milestone that removes a significant development barrier for Arbutus' lead oral PD-L1 inhibitor program. This is a positive operational/regulatory event that enables continued clinical development, but does not fit the specific categories of earnings release, executive changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. It is clearly operational in nature and material to investors assessing the company's pipeline progress.","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41627,"accession_number":"0001171843-26-006753","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's lifting of the clinical hold on AB-101's IND application is a material regulatory milestone that removes a significant development barrier for Arbutus' lead oral PD-L1 inhibitor program. This is a positive operational/regulatory event that enables continued clinical development, but does not fit the specific categories of earnings release, executive changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. It is clearly operational in nature and material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:32:38.584687+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41627,"accession_number":"0001171843-26-006753","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's lifting of the clinical hold on AB-101's IND application is a material regulatory milestone that removes a significant development barrier for Arbutus' lead oral PD-L1 inhibitor program. This is a positive operational/regulatory event that enables continued clinical development, but does not fit the specific categories of earnings release, executive changes, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction. It is clearly operational in nature and material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:32:38.584687+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-10-22"}]}